#pharma #metabolics #GLP1 #peptides #drugdevelopment #SunPharma #ChemOutsourcing Sun Pharma's Utreglutide shows promising results in obesity treatment GLP-1 Momentum Grows as SUN PHARMAs Utreglutide Shows Early Efficacy Sun Pharmas novel GLP-1 receptor agonist, Utreglutide, delivered compelling results in a Phase 1b/2a study: participants lost around 8% of body weight at 14 weeks and saw a near-30% drop in liver-fat content
Now, obesity, diabetes, and insulin resistance are all issues that impact women's fertility and ability to carry a healthy pregnancy, because there are hormones that are stored in the fatty tissue that work against the natural, typical process that helps people get pregnant
Hence, the attachment of an extra tail seems unnecessary
Also, the role of IF has been studied in clinical trials
That 48-week timeframe for retatrutide is shorter than the semaglutide and tirzepatide trials, which makes the comparison even more striking